American Vanguard (AVD) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 net sales declined 3–3.4% year-over-year to $128.2M, with adjusted EBITDA margin falling to 4.8% from 8.2% and EPS at $(0.42) vs. $(0.04); H1 2024 net sales rose 2–2.8% to $263.4M.
Profitability was impacted by non-recurring transformation and severance costs, with operating expenses up 20% and transformation charges totaling $9.3M in Q2.
Leadership transition included the formation of an Office of the CEO and a CEO search, with a focus on transformation, cost reduction, and margin improvement.
Workforce reduction of 4% and other cost-saving initiatives are expected to yield $15M in annualized savings by 2026.
Amended credit facility was entered to relax EBITDA covenants, improve borrowing capacity, and restrict dividends, buybacks, and acquisitions without lender consent.
Financial highlights
Q2 2024 net sales: $128.2M (down 3–3.4% year-over-year); H1 2024 net sales: $263.4M (up 2–2.8%).
Q2 2024 gross profit: $37.8M (down 12%); gross margin: 29% (down from 32%).
Q2 2024 operating expenses: $47.0M (up 20%), including $7.3M–$9.3M in transformation costs.
Q2 2024 net loss: $11.7M; H1 2024 net loss: $10.2M.
Debt at June 30, 2024: $210.2M–$211.3M; cash at $17.9M.
Outlook and guidance
Full-year 2024 adjusted EBITDA target lowered to $40M–$50M (from $60M–$70M); sales target now $565M–$580M, down from prior 6–9% growth guidance.
Targeting a 15% adjusted EBITDA margin by 2026 through transformation and efficiency gains.
Working capital expected to decrease by $70M–$80M in the second half of 2024.
Management expects continued pressure from low commodity prices, high input costs, and elevated interest rates.
Liquidity is expected to be sufficient for the next twelve months.
Latest events from American Vanguard
- 2025 margins improved and losses narrowed; 2026 targets higher EBITDA and growth from new products.AVD
Q4 202516 Mar 2026 - Q3 loss and sales drop driven by recall, but guidance and non-crop growth remain strong.AVD
Q3 202415 Jan 2026 - Transformation plan aims for 15% EBITDA margin and growth in biologicals by 2025.AVD
Gabelli Funds' 16th Annual Specialty Chemicals Symposium26 Dec 2025 - 2024 EBITDA met guidance as debt and inventory fell; 2025 targets higher revenue and margin.AVD
Q4 202424 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve performance-based executive pay.AVD
Proxy Filing2 Dec 2025 - Adjusted EBITDA up 350%, gross margin 29%, and net loss narrowed on strong U.S. crop sales.AVD
Q3 202517 Nov 2025 - Q1 sales dropped 14% with a net loss, but cost cuts and lower debt support recovery.AVD
Q1 202514 Nov 2025 - Adjusted EBITDA nearly doubled and gross margin hit a five-quarter high as net loss narrowed.AVD
Q2 20257 Aug 2025